博拓生物(688767) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was CNY 100,162,558.53, a decrease of 56.96% compared to the same period last year[5] - Net profit attributable to shareholders was CNY 29,925,011.27, down 78.60% year-on-year[5] - The net profit after deducting non-recurring gains and losses was CNY 22,573,407.69, reflecting an 83.10% decrease compared to the previous year[5] - Total revenue for the first three quarters of 2023 was ¥312,238,836.62, a significant decrease from ¥1,756,664,370.19 in the same period of 2022, representing a decline of approximately 82.24%[20] - Net profit for the first three quarters of 2023 was ¥90,060,965.64, compared to a net loss of ¥885,426,852.43 in the same period of 2022, marking a turnaround in profitability[21] - The company achieved an operating profit of ¥91,093,805.66 in Q3 2023, a significant decrease from ¥1,040,889,850.16 in Q3 2022[21] - The total comprehensive income for the first three quarters of 2023 was ¥91,077,493.37, compared to ¥887,005,092.51 in the same period of 2022, reflecting a substantial decline[22] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,554,262,236.27, a decrease of 7.16% from the end of the previous year[5] - Total assets as of September 30, 2023, are approximately ¥2.55 billion, down from ¥2.75 billion at the end of 2022, a decrease of 7.15%[15] - Total liabilities decreased to ¥131,377,729.41 in Q3 2023 from ¥188,920,067.64 in Q3 2022, reflecting a reduction of approximately 30.49%[20] - Total equity attributable to shareholders decreased to ¥2,419,035,665.06 in Q3 2023 from ¥2,561,259,556.96 in Q3 2022, a decline of about 5.55%[20] Cash Flow - Cash flow from operating activities showed a significant decline, with a net amount of CNY 36,490,523.60, down 95.37% year-to-date[5] - In the first three quarters of 2023, the net cash flow from operating activities was ¥36,490,523.60, a significant decrease of 95.37% compared to ¥787,383,433.41 in the same period of 2022[25] - Total cash inflow from operating activities was ¥404,508,892.26, down 82.09% from ¥2,261,432,862.44 in the previous year[25] - Cash outflow from operating activities totaled ¥368,018,368.67, a reduction of 75.05% compared to ¥1,474,049,429.03 in 2022[25] - The net cash flow from investing activities was ¥107,005,914.12, a turnaround from a negative cash flow of ¥153,709,277.36 in the same period last year[26] - The net cash flow from financing activities was -¥236,743,434.40, consistent with the previous year's negative cash flow of -¥341,936,869.38[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,443[11] - The largest shareholder, Hangzhou Tuokang Investment Co., Ltd., holds 24,896,000 shares, accounting for 23.34% of total shares[11] - The company has a total of 10 major shareholders with varying ownership percentages, with the top three holding a combined 51.30%[12] Research and Development - Research and development expenses totaled CNY 15,156,563.71, down 36.76% year-on-year, while the R&D expense ratio to revenue increased to 15.13%[5] - Research and development expenses for the first three quarters of 2023 were ¥43,745,658.93, down from ¥93,275,444.52 in 2022, indicating a reduction of approximately 53.06%[20] Market and Product Development - The company attributed the significant declines in revenue and profit primarily to a sharp decrease in sales of COVID-19 testing products[9] - The company has not reported any significant new product developments or market expansions during this reporting period[13]